Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

NCT07061574 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07061574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07061574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 10, 2026
Completion date
April 15, 2031
Enrollment
120 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

new onset, type 1 diabetes